Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06639425
NA

Efficacy of Lactobacillus Paracasei LC19 on Type 2 Diabetes

Sponsor: Beijing Chao Yang Hospital

View on ClinicalTrials.gov

Summary

This is a randomized, double-blind, placebo-controlled clinical trial. The objective of this trial is to determine whether Lactobacillus paracasei LC19 supplementation has a positive effect on glucose lowering in patients with type 2 diabetes (T2D).

Official title: Efficacy of Lactobacillus Paracasei LC19 on Newly Diagnosed Type 2 Diabetes

Key Details

Gender

All

Age Range

18 Years - 65 Years

Study Type

INTERVENTIONAL

Enrollment

60

Start Date

2024-10-12

Completion Date

2026-12-31

Last Updated

2025-02-07

Healthy Volunteers

No

Conditions

Interventions

DIETARY_SUPPLEMENT

Lactobacillus paracasei LC19 supplementation

Orally administered Lactobacillus paracasei LC19 strain product, in addition to lifestyle intervention. This product is a probiotic milk powder, and the Lactobacillus paracasei LC19 strain is capable of producing high levels of tryptophan-conjugated cholic acid (Trp-CA)( 25g/packet, 2 packets/day).

DIETARY_SUPPLEMENT

Placebo probiotic milk powder

Orally administered placebo probiotic milk powder, in addition to lifestyle intervention. The placebo probiotic strain also belongs to Lactobacillus paracasei species, but does not produce Trp-CA. These products have the same color, odor, appearance, and packaging (25g/packet, 2 packets/day).

Locations (1)

Beijing Chao-yang Hospital, Capital Medical University

Beijing, Beijing Municipality, China